Transgene SA
EPA:TNG.PA
Overview | Financials
Company Name | Transgene SA |
Symbol | TNG.PA |
Currency | EUR |
Price | 0.871 |
Market Cap | 122,769,261 |
Dividend Yield | 0% |
52-week-range | 0.834 - 1.528 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Alessandro Riva M.D. |
Website | https://www.transgene.fr |
An error occurred while fetching data.
About Transgene SA
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD